SLC9A1 and central nervous system cancer: Most importantly, our recent study shows that temozolomide (TMZ) treatment induces glioma cells to upregulate NHE1 protein expression in an intracranial mouse syngeneic glioma model bearing SB28-GFP (non-immunogenic) or GL26-Cit tumors (immunogenic) [18].